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Duration of Immunity against Mycobacterium bovis following
Neonatal Vaccination with Bacillus Calmette-Guérin Danish:
Significant Protection against Infection at 12, but Not 24, Months
M. L. Thom,a M. McAulay,a H. M. Vordermeier,b D. Clifford,b R. G. Hewinson,b B. Villarreal-Ramos,a,b and J. C. Hopea*
Institute for Animal Health, Compton, Newbury, Berkshire,a and Animal Health and Veterinary Laboratories Agency Weybridge, New Haw, Addlestone, Surrey,b United
Kingdom
Vaccination of neonatal calves with Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces a significant degree of protec-
tion against bovine tuberculosis, caused by infection with virulent M. bovis. In two independent experiments, we assessed the
duration of the protective immunity induced in calves by neonatal vaccination with BCG Danish. Protection from disease was
assessed at 12 and 24 months postvaccination in cattle challenged via the endotracheal route with M. bovis. We also assessed an-
tigen-specific immune responses to assess their utility as correlates of protection. At 12 months postvaccination, significant re-
ductions in lung and lymph node pathologies were observed compared to nonvaccinated M. bovis-challenged control cattle. At
24 months post-BCG vaccination, there was a reduction in lung and lymph node pathology scores and in bacterial burden. How-
ever, when comparing vaccinated and control groups, this did not reach statistical significance. Vaccination induced long-lived
antigen (purified protein derivative [PPD])-specific gamma interferon (IFN-) release in whole-blood cultures, which remained
above baseline levels for more than 20 months (approximately 90 weeks). The number of antigen-specific IFN--secreting cen-
tral memory T cells present at the time of M. bovis challenge was significantly higher in vaccinated than in control animals at 12
months postvaccination, but not at 24 months. Vaccination of neonatal calves with BCG Danish induced protective immune
responses against bovine TB which were maintained for at least 12 months postvaccination. These studies provide data on the
immunity induced by BCG vaccination in calves; the results could inform vaccination strategies for the control of bovine TB in
United Kingdom cattle herds.
Bovine tuberculosis (bTB) affects a significant number of cattlein theUnited Kingdom, with associated economic and animal
welfare concerns. The incidence of bovine TB continues to rise,
withmore than 10%of cattle herds in England currently under TB
restrictions. Currently, the diagnosis of bovine TB is by tuberculin
skin test combined with ancillary blood tests to detect antigen-
specific gamma interferon (IFN-) secretion. Cattle which test
positive are subsequently culled fromaffected herds.However, the
control of bTB is complicated by the presence ofM. bovis-infected
wildlife species, including the Eurasian badger, which act as reser-
voirs of infection. It is clear that improved control strategies are
required to reduce the incidence of bTB.
Vaccination could be an important element of bovine TB con-
trol in the future. Currently, the only licensed vaccine against hu-
manTB is bacillus Calmette-Guérin (BCG), an attenuated formof
Mycobacterium bovis. Alternative approaches to BCG vaccination
have been assessed for efficacy in humans and in cattle (reviewed
in references 6 and 23). However, it has been shown that the most
effective strategies that induce protective immunity against bTB
are those that include BCG, either alone delivered to calves or as
the priming agent in heterologous prime-boost strategies (24, 30).
Vaccination of badgers with injectable BCG has been shown in
experimental studies to reduce the severity of disease and excre-
tion of M. bovis (8). In field trials, BCG vaccination of badgers
significantly reduced the number of badgers which tested positive
for TBwith the Stat-Pak antibody test, suggesting that vaccination
controlled the progression of disease (8, 20). Vaccination of bad-
gers with BCG has been deployed, on a limited basis, as a control
mechanism in England since 2010. Importantly, vaccination of
calves with BCG has been shown in a number of studies to induce
significant protection againstM. bovis infection (5, 7, 16, 34). Fol-
lowing vaccination with BCG Danish (the strain of BCG licensed
for human, and now badger, vaccination), significant reductions
in the number of TB lesions and the bacterial burden were ob-
served in the lungs and respiratory tract-associated lymph nodes
(LN) ofM. bovis-challenged calves (16, 34).
Although a major constraint to the use of BCG as a cattle vac-
cine is interferencewith detection of bTBby tuberculin-based skin
test and IFN- detection methods, diagnostic tests utilizing M.
bovis-specific antigens can be employed to distinguish vaccinated
from infected animals in tests for differentiating infected from
vaccinated animals (DIVA tests) (3, 4, 9, 29, 31). The implemen-
tation of such tests could facilitate the deployment of BCG as a
cattle vaccine for bTB control, subject to amendments in EU leg-
islation.
An important consideration is the duration of immunity in-
duced by BCG vaccination. We performed studies to determine
the duration of protective immunity: calves were vaccinated with
BCG and challenged withM. bovis 12 or 24 months postvaccina-
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tion. We report here that reductions in pathology and bacterial
burden were evident at 12 and 24 months following vaccination,
with significant protection from M. bovis challenge evident at 12
months.
MATERIALS AND METHODS
Animals and experimental plan. Cattle were British Holstein-Friesian
calves (Bos taurus) bred at the Institute for Animal Health. The IAH herd
has been confirmed free from bovine TB for more than 10 years. Two
separate experiments, each with groups of age-matched vaccinated and
control calves, were performed. Animals were vaccinated with BCGwhen
between 10 days and 29 days of age (experiment 1: median age at vacci-
nation, 17 days; range, 10 to 27 days; experiment 2: median age at vacci-
nation, 25 days; range, 19 to 29 days). Controls were age-matched, non-
vaccinated calves. Calves were assigned to groups (9 animals per group)
according to age and preexisting responses tomycobacterial antigens (de-
termined as purified protein derivative [PPD]-specific IFN- [see be-
low]). Approximately 12 (experiment 1) or 24 (experiment 2) months
after vaccination, cattle were transferred into a high-security Advisory
Committee on Dangerous Pathogens (ACDP) category 3 animal housing
unit at the Animal Health and Veterinary Laboratories Agency (AHVLA)
in Weybridge and infected with M. bovis via the endotracheal route.
Twelve weeks after infection, tuberculin skin tests were performed. The
animals were killed 1 week later, and postmortem examinations were
performed as described below. The experiments were approved by the
local ethics committee according to national United Kingdom guidelines.
Bacteria and calf inoculations. BCGDanish (batch numbers 104051C
and 106052A, used in experiments 1 and 2, respectively) was purchased from
Statens Serum Institut (SSI), Denmark, and reconstituted immediately prior
to use in 1ml Sautonmedium.Calves were inoculated subcutaneously in the
left shoulder with 0.5 ml (5 times the recommended human dose) of BCG
Danish (16). This corresponds to a dose of 1 106 to 4 106CFUaccording
to the manufacturer’s specifications. For challenge, M. bovis (strain AF
2122/97 [13])wasdiluted immediatelyprior to inoculation fromfrozen stock
in 7H9 medium. Cattle were inoculated endotracheally as previously de-
scribed (30). The dose of M. bovis was confirmed by titration on modified
7H11 agar (12) and determined to be approximately 2 103 CFU per calf.
Postmortem examination and bacteriology. Lymph nodes of the
head (lateral and medial retropharyngeal, submandibular, and parotid)
and thorax (caudal and cranial mediastinal, bronchial left and right, and
cranial tracheo-bronchial), tonsils, nasal and tracheal mucosa, and pul-
monary lobeswere examined for gross lesions following the cutting of 0.5-
to 1-cm slices. Macroscopic lesions were scored using the semiquantita-
tive systems described here and previously (28).
(i) Lungs. Lung lobes (left apical, left cardiac, left diaphragmatic, right
apical, right cardiac, right diaphragmatic, and right accessory) were ex-
amined individually. For each lobe, the following scoring system was ap-
plied: 0, no visible lesions; 1, no gross lesions but lesions apparent upon
slicing; 2,5 gross lesions with diameters of10mm; 3,6 gross lesions
with diameters of10mmor a single distinct gross lesionwith a diameter
of10mm; 4,1 distinct gross lesionwith diameter of10mm; 5, gross
coalescing lesions. The scores of the individual lobes were added up to
calculate the lung score for each animal.
(ii) Lymph nodes. The severity of the observed gross pathology in
individual lymph nodes was scored by use of the following scoring system:
0, no necrosis or visible lesions; 1, small focus (1 to 2 mm in diameter); 2,
several small foci or a necrotic area of at least 5 by 5 mm; 3, multiple
necrotic areas of at least 5 by 5 mm distributed throughout the node or
one necrotic area affecting 5% of the node. Individual lymph node
scores were added up to calculate the lymph node score. Both lymph node
scores and lung pathology scores were added to determine the total pa-
thology score per animal. All scoring was performed by the same operator
for all animals to ensure scoring consistency. Tissues were fixed in 10%
formal saline and processed for histological examination following stain-
ing with hematoxylin and eosin. Tissues with typical lesions of TB evident
by microscopy, but no gross lesions, were given a score of 1 in the overall
pathology comparison. Tissue samples were frozen at 70°C for subse-
quent bacteriological examination by titration of tissue homogenates on
modified 7H11 agar (12). Colonies per individual lymph node sample
were calculated, and CFU loads of individual lymph node samples were
added up to estimate the bacillary content in a given animal.
Antigens for whole-blood assays. Purified protein derivatives from
Mycobacterium avium (PPD-A) and M. bovis (PPD-B) were obtained
from the Tuberculin Production Unit at the AHVLA, Weybridge. For all
in vitro assays, Weybridge PPDs were used (1 mg/ml; 25,000 IU/ml). Re-
combinant ESAT-6 and CFP-10 were as described previously (9). These
antigens are expressed by M. bovis but not by BCG and can be used to
discriminate between vaccinated and infected individuals.
Tuberculin skin tests. The single comparative intradermal tuberculin
test with avian and mammalian PPDs (PPD-A and PPD-B, respectively)
was by intradermal inoculation of 0.1 ml of PPD-A and PPD-B, and reac-
tions were read 72 h later. In experiment 1 (12 months postvaccination),
Weybridge PPD was used (1 mg/ml; 25,000 IU/ml). For experiment 2 (24
months postvaccination), PPD was obtained from Prionics AG, Switzer-
land (potencies of 25,000 IU/ml and 30,000 IU/ml for PPD-A and PPD-B,
respectively). Results were recorded as the increase in skin thickness at 72
h compared to thickness preinjection and interpreted according to the
standard protocol (European Commission Directive 64/432/EEC, as
amended [25]).
Immunological assays. Blood was collected into tubes with heparin
(10U/ml). For cytokine assays, 4ml of bloodwas incubated at 37°C for 24
h with PPD-A or PPD-B (final concentration of 20 g per ml) diluted in
RPMIwith 50g/ml gentamicin. ESAT-6 and CFP-10 were used at a final
concentration of 5g/ml. An equal volume of RPMIwith gentamicin was
used as a control. The supernatant was removed after centrifugation and
stored at 20°C until assayed. IFN- levels were determined in an en-
zyme-linked immunosorbent assay (ELISA) as described elsewhere, using
recombinant bovine IFN- as a standard (19). Each sample assayed was
measured in duplicate by ELISA; the variability between samples was less
than 5%.
Cultured ELISPOT. Secretion of IFN- by cultured peripheral blood
mononuclear cells (PBMC) was also assessed by cultured enzyme-linked
immmunosorbent spot (ELISPOT) assay, as previously described (36,
37). Briefly, PBMC were stimulated in 24-well plates (2 106 PBMC/ml,
1-ml aliquots) with PPD-B at 10 g/ml. Cells were fed on days 5 and 8
with recombinant bovine intereukin-2 (IL-2; 10U/ml) andondays 10 and
12 with fresh tissue culture medium. On day 13, 104 cultured cells were
added to wells of ELISPOT plates (17) and cultured together with antigen
(PPD-A and PPD-B at 10 g/ml). To each well, 1  103 autologous
monocyte-derived dendritic cells (15) were added. Cells were cultured for
24 h, and spots were developed (17, 37). Results are expressed as the
number of spot-forming cells (SFC) per 106 PBMC.
Statistical analyses. Analyses were performed using Minitab version
15. The degree of pathology between BCG-vaccinated and control calves
was compared using the Mann-Whitney test, and the degree of bacterial
colonization between BCG-vaccinated and control calves was compared
using the t test on logarithmically transformed counts. For analysis of
central memory antigen-specific T cell responses, the data for the control
groups were pooled and compared to the vaccinated groups in nonpara-
metric analyses of variance. P values of0.05 were considered significant.
RESULTS
Vaccination with BCG Danish in neonatal calves induces signif-
icant protection against M. bovis challenge at 12 months, but
not 24 months, postvaccination. In order to establish the dura-
tion of immunity induced by neonatal BCGvaccination, groups of
neonatal calves were vaccinated with BCGDanish within 1month
of birth. Age-matched control calves were not vaccinated. Ap-
proximately 12 months (week 54) or 24 months (week 112) later,
calves were challenged endotracheally with M. bovis. The protec-
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tive efficacy of BCG vaccination against disease was assessed by
postmortem examinations performed 12 weeks postchallenge for
all animals (Tables 1 and 2). None of the animals showed clinical
signs of disease. Although the extent of lesions varied between
animals, as reflected by the lesion scores (Table 1), in each case
lesionswere primarily restricted to the respiratory tract-associated
lymph nodes and lungs.
In animals infected with M. bovis 12 months postvaccination
(Table 1), lesions typical of TB were observed in all but one of the
nonvaccinated controls, in both lymph nodes and lung. Two an-
imals in the BCG-vaccinated group had no evidence of lesions.
BCG Danish conferred significant protection against M. bovis
challenge, with reduced total gross pathology (P  0.0373) and
significantly reduced lung pathology scores (P 0.0303). Lymph
node pathology scores were also substantially reduced in vacci-
nated animals, although this reduction did not quite reach statis-
tical significance (P 0.0685).
Lesions typical of TB were observed in all of the animals chal-
lenged 24 months postvaccination, irrespective of their vaccina-
tion status (Table 2). Although there was a tendency toward lower
lesion scores within the BCG-vaccinated group, no significant dif-
ference in overall pathology between BCG-vaccinated and control
cattle was observed (P  0.1428). No statistically significant dif-
ference was observed in lymph node (P  0.3473) or lung (P 
0.1304) pathology scores between BCG-vaccinated and control
animals. Overall, although an approximately 20% reduction in
lesion scores was evident in the BCG-vaccinated animals (Table
2), this was not a statistically significant decrease.
BCG vaccination of neonatal calves reduces the level of bac-
terial colonization. Neonatal BCG vaccination reduced the sever-
ity of disease following M. bovis infection. In order to assess
whether this was associated with effects on bacterial burden, we
measured numbers of bacteria present within the respiratory
tract-associated lymph nodes. Bacteriological examination of tis-
sues indicated thatM. bovis was present in the majority of tissues
with gross lesions in both experiments (Tables 1 and 2). In cattle
challenged 12 months postvaccination (Table 1), 3/9 animals in
the BCG-vaccinated group had no viable M. bovis cultured from
tissues. However, overall there was no significant difference in the
number of viableM. bovis (CFU/LN) between control and vacci-
nated cattle (P 0.189). In the cattle challenged 24 months post-
vaccination (Table 2), viable bacteria were isolated from the tis-
sues of all of the animals, and no significant differences were
observed between the BCG-vaccinated andnonvaccinated control
animals (P 0.733).
Skin test reactivity in BCG-vaccinated and control calves fol-
lowing M. bovis challenge. Reactions to PPD in the skin test were
observed in the majority of animals 12 weeks after challenge with
M. bovis (Tables 1 and 2). Visible local clinical signs and increases
in comparative skin thickness (the skin test thickness response to
PPD-B minus the response to PPD-A) ranging from 7 to 63 mm
were recorded. Relatively low responses to PPD-A were noted in
these animals.
In experiment 1 (animals challenged with M. bovis at 12
months postvaccination [Table 1]), one nonvaccinated animal
and two BCG-vaccinated animals showed no skin test reactivity.
These animals also had no visible lesions or viableM. bovis present
in tissues. However, 7/9 BCG-vaccinated and 8/9 control animals
would be classified as reactors according to the standard interpre-
TABLE 1 Pathology scores and bacteriological counts in animals
infected withM. bovis 12 months postvaccination
Test group and animal ID
Gross pathology score for:
CFU/LN
sample
Skin test
(PPD-B
PPD-A)a
Total LN
samples
Total lung
samples
All
samples
Control animals
402340 14 16 30 587,000 47
602342 20 6 26 1,142,000 53
502348 19 19 38 128,400 27
302353 9 7 16 483,480 25
502355 11 4 15 47,000 26
401361 15 13 28 990,400 37
102365 2 5 7 11,400 27
302367 8 5 13 92,200 36
602370 0 0 0 0 0
Median or mean valueb 11 6 16 386,875 30.9
BCG-vaccinated group
502341 10 3 13 842,020 49
702343 8 0 8 29,740 22
702350 1 0 1 0 7
402354 12 0 12 46,060 18
302360 9 7 16 310,020 8
202366 7 4 11 77,400 30
502369 0 0 0 0 0
102372 0 7 7 7,260 32
402375 0 0 0 0 0
Median or mean valueb 7 0 8 145,833 18.4
a Skin test thickness was recorded at day 0 and day 3 following inoculation with PPD-A
and PPD-B. PPD-B-specific increases in skin thickness at 72 h are shown (i.e., response
to PPD-B minus the response to PPD-A).
b For pathology scores, medians are shown; for CFU and skin test data, means are
shown.
TABLE 2 Pathology scores and bacteriological counts in animals
infected withM. bovis 24 months postvaccination
Test group and animal ID
Gross pathology score for:
CFU/LN
sample
Skin test
(PPD-B
PPD-A)a
Total LN
samples
Total lung
samples
All
samples
Control animals
C09-5134 4 7 11 2,400 40
C09-5135 4 6 10 1,753 18
C09-5136 5 4 9 62,700 63
C09-5137 4 4 8 8,297 27
C09-5138 3 5 8 467 18
C09-5139 10 5 15 79,020 17
C09-5140 7 10 17 53,500 57
C09-5141 10 7 17 47,187 21
C09-5142 5 5 10 2,167 28
Median or mean valueb 5 5 10 28,610 32.1
BCG vaccination group
C10-6123 4 4 8 1,813 27
C10-6124 3 4 7 45,900 20
C10-6125 5 4 9 47,027 10
C10-6126 9 4 13 5,040 30
C10-6129 3 4 7 2,373 15
C10-6130 8 9 17 11,420 28
C10-6127 7 7 14 16,260 38
C10-6128 0 5 5 1,040 45
C10-6131 3 3 6 4,147 16
Median or mean valueb 4 4 8 15,002 25.4
a Skin test thickness was recorded at day 0 and day 3 following inoculation with PPD-A
and PPD-B. PPD-B-specific increases in skin thickness at 72 h are shown (i.e., response
to PPD-B minus the response to PPD-A).
b For pathology scores, medians are shown; for CFU and skin test data, means are
shown.
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tation of the skin test. There were no significant differences be-
tween the groups (P 0.112).
All of the animals challenged at 24months postvaccination had
significant skin test reactivity (Table 2). There were no significant
differences between the groups (P 0.266), and each of the ani-
mals would be classified as reactors according to the standard
interpretation of the skin test.
BCG Danish induces long-lived antigen-specific IFN- re-
sponses in whole-blood cultures. We measured antigen-specific
IFN- secretion in BCG-vaccinated and control calves through-
out the experiment to monitor the course of the immune re-
sponse. Calves were vaccinated with BCG Danish and challenged
withM. bovis at 12 months postvaccination (experiment 1) or 24
months postvaccination (experiment 2) (Fig. 1).
In experiment 1 vaccination, with BCG Danish induced PPD-
B-specific immune responses that were evident at 2 weeks post-
vaccination (Fig. 1). Although the PPD-B-specific IFN- response
was reduced after 6weeks postvaccination, this was above the level
of PPD-B-specific IFN- observed in the control group for the
duration of the vaccination study (52 weeks). No PPD-B-specific
IFN- (i.e., levels were 500 pg/ml) was observed in the control
calves at any time point (data not shown).
Post-M. bovis challenge PPD-B-specific immune responses in
whole-blood cultures were observed from 4 weeks in both control
and vaccinated animals (Fig 1).Nodifferences between vaccinated
and control groups were observed for PPD-B-specific IFN- at
any time point post-M. bovis challenge.
In experiment 2 similar early kinetics of PPD-B-specific IFN-
induction were observed with the peak response evident between
2 to 8 weeks postvaccination. These responses remained generally
above the prevaccination levels up to 90 weeks post vaccination
(with the exception of weeks 32, 34, 64 and 66) (Fig. 1).
Post-M. bovis challenge, ESAT-6/CFP-10-specific IFN- secre-
tion was observed in all animals irrespective of vaccination status.
In the animals challenged at 12 months (Fig. 2), higher responses
were observed in the control group (closed symbols) from 4weeks
to 8 weeks following infection. No differences in reactivity to
ESAT-6/CFP-10 were observed between control and vaccinated
animals challenged at 24 months.
The frequency of antigen-specific IFN--secreting memory
cells present at the time of challenge correlates with protective
immunity. Detection of IFN--secreting central memory T lym-
phocytes in cultured ELISPOT assays was previously shown to
predict protection in BCG-vaccinated calves (16, 36) andwas used
here to assess whether the detection ofmemory T cells (Tcm) at 12
or 24months postvaccinationwas also predictive of efficacy. At 12
months (Fig. 3) or 24 months postvaccination (data not shown),
immediately prior to M. bovis challenge, PBMC were isolated
from all calves and cultured in the presence of antigen and IL-2 to
establish short-term T cell lines. Following 2 weeks of culture, the
presence of central memory T cells secreting IFN- was assessed
by ELISPOT. The frequency of PPD-B-specific SFC (response to
PPD-Bminus response to PPD-A)was calculated. The data for the
FIG 1 Antigen-specific IFN- secretion in whole-blood cultures. IFN- release from bovine whole-blood cultures stimulated with PPD-A (open squares),
PPD-B (closed squares), or medium (open circles) from animals vaccinated with BCGDanish (left panel, top graph), nonvaccinated control animals challenged
withM. bovis at 12 months (week 54) (left panel, bottom left graph), or vaccinated with BCGDanish at week 0 and challenged withM. bovis at 12 months (week
54) (left panel, bottom right graph). The panel on the right shows graphs for animals vaccinated with BCG Danish in experiment 2 (top graph), nonvaccinated
control animals challenged withM. bovis at 24 months (week 114) (bottom left graph), and animals vaccinated with BCGDanish at week 0 and challenged with
M. bovis at 24months (week 114) (bottom right graph). IFN- levels are expressed as groupmean ( standard error) plasma cytokine concentrations (in pg/ml).
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control animals were pooled for analysis, as no significant differ-
ences were noted between the two control groups.
Twelve months after vaccination of cattle with BCG Danish
(Fig. 3, black bars), numbers of antigen-specific IFN--expressing
central memory T lymphocytes were significantly higher than in
those in nonvaccinated control animals (P  0.02) (Fig. 3). In
contrast, the number of PPD-B-specific IFN--expressing central
memory T cells present in cattle 24 months postvaccination was
not significantly different from that observed in control animals.
DISCUSSION
Bovine tuberculosis is an economically important disease of in-
creasing incidence in United Kingdom cattle herds. Disease con-
trol is currently through the skin test and slaughter policy and
ancillary blood tests detecting tuberculin-induced cell-mediated
immune responses. The presence of the causative agent of bovine
TB, Mycobacterium bovis, in wildlife reservoirs impacts signifi-
cantly on the effectiveness of disease control. Hence, additional
control tools are required to reduce the incidence of bovine TB in
areas where bTB is endemic. An importantmechanism for control
is likely to be vaccination. As an attenuated form ofM. bovis, BCG
shares high homology with the virulent strain, and therefore vac-
cinated cattle also show skin test reactivity to tuberculin (PPD-B)
and also secrete antigen-specific IFN- in blood-based diagnostic
tests. However, despite numerous vaccine candidates having un-
dergone trials in cattle for efficacy against M. bovis infection, the
most successful strategies are those which include BCG either as a
single vaccine or as the priming agent in heterologous prime-
boost regimens (reviewed in references 6 and 33). Thus, differen-
tially expressed antigens between M. bovis and BCG, such as
ESAT-6, CFP-10, and other RD1 gene products, have been iden-
tified and used in diagnostic assessments to provide the capacity
for DIVA determinations (reviewed in reference 32).
Vaccination of calves with BCG is associated with significant
protective efficacy against virulent challenge with M. bovis (5, 7,
16, 17, 34). In these studies, vaccination within the first 4 weeks of
life was shown to induce significant reductions in disease-associ-
ated parameters, including lesion (pathology) scores and bacterial
burdenswithin the respiratory tract tissues. Protective efficacies of
approximately 70% were reported, with a significant number of
animals completely protected from disease.
In experimental studies of BCG vaccination of neonatal calves
(5, 7, 16, 17, 34), there was a relatively short duration between
vaccination and infectious challenge with M. bovis: on average, a
vaccination period of 3monthswas utilized. Given that dairy cows
have an average life span on farm of3 years, we sought to deter-
mine whether a single vaccination of calves would give long-last-
ing protection, or to define at what time point protective immu-
nity wanes. This would enable determination of time scales for
enhancing immunity through heterologous boosting or homolo-
gous revaccination.
In humans, neonatal vaccination with BCG has a significant
impact on childhood TB; however, a decline in BCG efficacy has
been reported over time/with age. These studies imply that a rel-
atively short duration of protection induced by BCG vaccination
may account, at least in part, for the variable efficacy of BCG
vaccination that has been reported in humanpopulations (10, 14).
Inmice, the duration of BCG-induced immunity was shown to be
less than 40 weeks, with a significant reduction in protective effi-
cacy observed between 20 and 40 weeks postvaccination (26).
Here, we have shown that vaccination of calves induces protec-
tive immunity against M. bovis challenge and that this is main-
tained for at least 12months following vaccination.We observed a
protective efficacy at 12 months similar to that previously re-
ported at 3 months neonatal vaccination (16). However, the pro-
tective immunity we observed had waned by 24 months. Thus,
although there was a reduction in each of the parameters assessed
in cattle challenged 2 years after vaccination (lung and lymph
node pathology scores and bacterial burdens), with the relatively
FIG 3 Frequency of antigen-specific IFN--secreting T lymphocytes present
at the time ofM. bovis challenge. At 12 months (BCG 12) or 24 months (BCG
24) post-BCG vaccination, memory cell responses were assessed by cultured
ELISPOT. The responses in control animals were also assessed: these were not
significantly different at either time point, and the data were therefore pooled
for analysis. The number of PPD-B-specific IFN- SFC present within PBMC
was significantly higher in vaccinated animals at 12 months, but not at 24
months, postvaccination, compared with control, nonvaccinated animals.
Mean standard deviations are shown (n 9 for vaccinated groups; n 18
for controls). *, P 0.05.
FIG 2 IFN- released following stimulation of whole blood with an ESAT-6/
CFP-10 cocktail. IFN- secretionwas assessed post-M. bovis challenge inBCG-
vaccinated (open symbols) and nonvaccinated control (closed symbols) ani-
mals. Animals were challenged withM. bovis 12 months postvaccination, and
blood was sampled and assessed biweekly. IFN- levels are expressed as the
group mean ( standard error) plasma cytokine concentration (in pg/ml).
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small group sizes utilized in our studies these reductions did not
reach statistical significance. However, this protective effect could
potentially have a positive impact on disease control in larger cat-
tle herds by reducing the overall level of disease and the numbers
of bacilli present.
It should also be noted that experimental challenge whereby
	103 CFUM. bovis are placed directly into the respiratory tract is
amore aggressive challenge than natural exposure, whereby trans-
mission occurs primarily through droplet inhalation of relatively
small numbers of bacilli. Interestingly, in a recent field study in
Ethiopia in which calves were vaccinated with BCG, Ameni et al.
showed that immunity against naturally transmitted M. bovis in-
fectionwas long-lived, with a duration of at least 23months (1). In
their studies, a significant proportion of completely protected cat-
tle with no visible lesions at postmortem examination was ob-
served. In similar studies performed in Mexico (22), the duration
of BCG-induced immunity against bTB was reported to wane at
around 12 months of age, in line with the results of our experi-
mental studies.
However, consideration will need to be given to the likelihood
that boosting of immunity will be required. In studies where
short-interval (6-week) homologous boosting of BCG-induced
immunity was assessed, no positive effect on the outcome of in-
fectious challenge was observed (7). However, the effects of ho-
mologous BCG boosting or revaccination with longer prime-
boost intervals (e.g., 1 year post-initial BCG vaccination) have not
yet been assessed, but such boosting could stimulate longer-dura-
tion protection, as the initial immunity starts to wane. Heterolo-
gous prime-boost strategies, utilizing viral vectors such as human
adenovirus or modified vaccinia virus Ankara which express im-
munodominant antigens such as Ag85A, have been shown to be
superior to BCG alone in protecting cattle fromM. bovis (30) and
are currently in phase IIB clinical trials in humans for vaccination
againstMycobacterium tuberculosis infection (23, 24). The capac-
ity for these strategies to boost BCG-induced immunity for life-
long protection for cattle should be assessed.
Identification of predictors of protective immunity is an essen-
tial part of vaccine research. The capability to determine whether
vaccines bestow protective immune responses prior to infectious
challenge will enablemore high-throughput studies, allowing pri-
oritization of candidates for efficacy studies. This not only will
reduce the time scales for vaccine evaluation but also will signifi-
cantly reduce the costs of vaccine studies and reduce the severity of
animal procedures. A number of candidate immunological pre-
dictors have been identified in TB vaccine studies. In studies of
neonatal BCG vaccination, we showed that protective efficacy was
correlated with the number of PPD-B-specific central Tcm pres-
ent at the time of M. bovis challenge (16), in line with previous
studies of vaccine-induced protection from bTB (30, 36). Con-
firming this observation, we showed here that when measured 12
months postvaccination, the numbers of Tcm determined by cul-
tured ELISPOT were higher in vaccinated than control animals,
and this corresponded to protection from infection overall. How-
ever, by 24 months postvaccination we were unable to show a
significant difference in the numbers of Tcm between vaccinated
and control cattle. Significantly increased numbers of PPD-B-spe-
cific Tcm in vaccinated cattle are thus only present in groups of
cattle where protective immunity is observed, suggesting that this
may be a predictive correlate of BCG-induced protection.
The relationship of IFN- secretion to protective efficacy is
complex: while it is clear that successful vaccination requires the
induction of IFN-, detection of IFN- alone is not a sufficient
biomarker of protection (18, 27, 33). We observed increased an-
tigen-specific IFN- secretion for up to 90 weeks following vacci-
nation, but we could not correlate this with the observed levels of
protection from M. bovis challenge. In studies of the duration of
BCG-induced immunity inmice, IFN- responses ofCD4
Tcells
toM. tuberculosis antigens were maintained despite a loss of pro-
tection between 20 and 40weeks postvaccination (26).More com-
plex measurements of polyfunctional T cells have revealed that
multiparametric responses of lymphocytes are required for pro-
tective immunity against M. tuberculosis in humans and mice (2,
11, 21). Recent studies in cattle have established methods for the
measurement of multifunctional T cells expressing IFN-, IL-2,
and tumor necrosis factor alpha in M. bovis infection (35), and
these may now be applied to vaccine studies to facilitate the defi-
nition of predictors of vaccine success. Application of such tech-
niques to future vaccination studies of neonatal calves may be
useful in defining predictors and correlates of protection.
In summary, we have shown that BCG vaccination of calves
induces a significant degree of protective immunity that lasts for at
least 12months but that this wanes by 24months postvaccination.
These results will inform future studies of the use of BCG vacci-
nation in conjunction with strategies for boosting immunity or
revaccination for longer-term protection fromM. bovis infection.
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